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Introduction
Stem cell therapy for skeletal and cardiac disease is a promising 
strategy  to  promote  regeneration  of  tissues  characterized  by 
slow cellular turnover (Nadal-Ginard et al., 2005; Anversa et al., 
2006; Yi et al., 2010). Skeletal muscle is actively repaired by 
satellite cells that sustain tissue regeneration and replace dam-
aged fibers. The heart, in contrast, forms scar tissue after injuries 
and was once considered a postmitotic organ without regenerative 
capacity.  Data  initially  obtained  from  sex-mismatched  cardiac 
transplants led to the identification and characterization of 
resident stem cells able to migrate into heart ischemic re-
gions (Quaini et al., 2002; Beltrami et al., 2003). Other cardiac 
stem/progenitor cells with similar characteristics were rap-
idly identified by several groups on the basis of differential 
marker  expression  and  ability  to  differentiate  into  one  or 
more cell types of the heart (Oh et al., 2003, 2004; Beltrami   
et al., 2005; Laugwitz et al., 2005). We recently showed that 
pericyte-derived cells (Dellavalle et al., 2007), termed meso-
angioblasts, are present in skeletal muscle and heart, show limited 
self-renewal, and undergo skeletal (Sampaolesi et al., 2003, 
2006) and cardiac (Galvez et al., 2008, 2009) myogenesis, re-
spectively.  The  number  of  proliferating  cardiac  progenitors 
strongly increases in acute and chronic diseases, although they 
P
ostnatal heart stem and progenitor cells are a po-
tential therapeutic tool for cardiomyopathies, but 
little is known about the mechanisms that control 
cardiac differentiation. Recent work has highlighted an 
important role for microribonucleic acids (miRNAs) as 
regulators of cardiac and skeletal myogenesis. In this 
paper, we isolated cardiac progenitors from neonatal 
-sarcoglycan  (Sgcb)–null  mouse  hearts  affected  by   
dilated  cardiomyopathy.  Unexpectedly,  Sgcb-null  car-
diac progenitors spontaneously differentiated into skele-
tal muscle fibers both in vitro and when transplanted into 
regenerating muscles or infarcted hearts. Differentiation 
potential correlated with the absence of expression of a 
novel miRNA, miR669q, and with down-regulation of 
miR669a. Other miRNAs are known to promote myo-
genesis, but only miR669a and miR669q act upstream 
of myogenic regulatory factors to prevent myogenesis by 
directly targeting the MyoD 3 untranslated region. This 
finding reveals an added level of complexity in the mech-
anism of the fate choice of mesoderm progenitors and 
suggests that using endogenous cardiac stem cells thera-
peutically will require specially tailored procedures for 
certain genetic diseases.
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important role in myogenic regulation. These data indicate that 
ex vivo gene therapy for muscle disease might not work in all 
cases and show that miR669a and the novel miR669q are able 
to rescue, at least partially, postinfarct cardiac degeneration in 
Sgcb-null mice by inhibiting MyoD expression that otherwise 
impairs cardiac progenitors.
Results
Sgcb-null cardiac progenitors show an 
aberrant differentiation pattern toward 
skeletal muscle
Hearts were collected from 2-wk-old Sgcb-null mice, and under 
a dissecting microscope, the aortic outflow tract, ventricle, or 
atrium was isolated, further dissected into small fragments, and 
plated on 1% gelatin-coated dishes as previously described 
(Tonlorenzi et al., 2007). After an initial outgrowth of fibroblast-
like cells, small round and poorly adhering cells appeared. 
These cells could be detached by gently pipetting and cloned by 
limiting dilution (Fig. S1 A). We selected three clones for each 
heart region (atrium: G5, G2, and B5; ventricle: H4, B9, and 
B3; and aorta: A4, A9, and D10). Southern blot and PCR analy-
ses confirmed the absence of the Sgcb gene in selected clones 
(Fig. S1 B). Cells in culture maintained a relatively constant 
proliferation rate until 20 population doublings comparable with 
the wild-type (wt) clone (Fig. S1 C), normal karyotype (Fig. S1 D), 
and a constant telomerase activity (Fig. S1 E). Sgcb-null cardiac 
clones were analyzed by flow cytometry for the expression of 
stem cell surface markers. All clones expressed Sca-1, CD34, 
CD44, and, weakly, CD31 and c-Kit. CD56, CD45, and CD13, 
markers for skeletal myoblasts, hematopoietic cells, and endothe-
lial cells, respectively, were not expressed (Fig. S1 F and Table I). 
All clones robustly expressed pericyte markers, such as smooth 
muscle actin (SMA), NG2, and PDGFR- (Fig. S1 G) and 
were positive for AP, whose activity is associated with pericyte 
cells (Fig. S1 H).
RT-PCR revealed widespread expression of cardiac mark-
ers, such as Nkx2.5, Mef2A, GATA4, and Cx43. In contrast, Isl-1, 
Tbx5, and myocardin were exclusively expressed in atrium, 
aorta, and ventricle clones, respectively. Atrial natriuretic pep-
tide was expressed only in atrium and ventricle clones (Fig. S1 I). 
Changes in gene expression were evaluated by time course 
quantitative PCR (qPCR) on wt (J8 ventricle [Ven] wt) and 
Sgcb-null (H4 Ven knockout [KO]) ventricle clones at 0, 5, and 
7 d in serum starvation. Pericyte markers (SMA, PDGFR-, 
and NG2) and early cardiac markers (Nkx2.5, Mef2A, and 
GATA4) were progressively down-regulated during differentia-
tion in both wt and Sgcb-null progenitors (Fig. S1 J). As expected, 
appear unable to counteract progressive degeneration, likely be-
cause they may get exhausted and senescent in repeated and un-
successful  attempts  to  regenerate  the  failing  heart  (Beltrami   
et al., 2001; Urbanek et al., 2005).
Chronic cardiac diseases are frequent findings in several 
forms of muscular dystrophy, including limb-girdle muscular 
dystrophies, caused by mutations in the sarcoglycan proteins 
that are involved in the maintenance of muscle integrity dur-
ing contraction. Mutations in the Sgcb gene cause LMD2E 
(limb-girdle muscular dystrophy type 2E), often character-
ized  by  severe  cardiomyopathy  and  mild  muscle  wasting. 
Similarly,  Sgcb-null  mice  develop  severe  cardiomyopathy 
with extensive regions of necrosis, fibrosis, and fatty infiltra-
tions (Durbeej et al., 2000). Although not much is known   
on the control of cardiac differentiation in adult progenitor 
cells, recent studies have highlighted the role of microRNAs   
(miRNAs) in controlling different aspects of muscle func-
tions (Bi et al., 2003; Bartel, 2004; van Rooij et al., 2009). 
miR1 and miR133 modulate muscle growth and differentia-
tion (Liu et al., 2008; van Rooij et al., 2007, 2008), whereas 
miR206 specifically promotes skeletal myogenesis (McCarthy, 
2008; Yuasa et al., 2008; Williams et al., 2009). Moreover, it 
has been shown that miRNAs governing muscle performance 
are encoded by myosin genes (van Rooij et al., 2009). So far, 
all the identified muscle miRNAs indirectly promote myo-
genesis, rather than acting directly on key regulatory factors 
for muscle differentiation.
To develop an ex vivo gene therapy approach for LG-
MD2E, we isolated and characterized cardiac progenitors from 
Sgcb-null mice on the basis of different cardiac progenitor 
markers (Beltrami et al., 2003; Oh et al., 2003; Laugwitz et al., 
2005; Bu et al., 2009). Here, we report that Sgcb-null cardiac 
progenitors display an aberrant activation of skeletal muscle 
genes that are normally silenced in healthy cardiac progenitors 
and differentiate into skeletal muscle fibers both in vitro and   
in vivo. This is because of the lack of miR669q, a novel identified 
miRNA encoded by the Sgcb gene, and the down-regulation of 
miR669a. miR669q shows high homology with miR669a and 
the other members of the miR669 family encoded as a cluster in 
Sfmbt2 gene, which is involved in epigenetic silencing of skele-
tal muscle genes (Wu et al., 2007; Liang et al., 2009). To date, 
among the miRNAs known to regulate skeletal myogenesis, 
only miR669a and miR669q directly inhibit the MyoD 3 un-
translated region (UTR) and, consequently, skeletal myogen-
esis. Gain- and loss-of-function experiments show that these 
miRNAs act within a network to control cardiac–skeletal mus-
cle fate switch in vitro and in vivo. A delay of skeletal muscle 
regeneration in muscles overexpressing miR669a confirms its 
Table I.  Characterization of Sgcb-null clones by FACS analysis
Clone G5 At G2 At B5 At H4 Ven B9 Ven B3 Ven A4 Aor A9 Aor D10 Aor
ISL1 + + +   +   
Sca1 ++ ++ ++ +++ +++ ++ ++ + +
c-Kit + + +  +  ++ + +
Summary of clones isolated from Sgcb-null hearts and characterized for the expression of cardiac stem cell markers ( < 10%; 10% < + < 30%; 30% < ++ < 70%; 
70% < +++ < 100%). At, atrium; Ven, ventricle; Aor, aorta.1199 Switch from cardiac to skeletal muscle lineages • Crippa et al.
Figure 1.  Myogenic potential of Sgcb-null cardiac progenitors. (A) Western blot analysis for the expression of skeletal muscle transcription factors (MyoD, 
Myf5, Pax3, and Pax7) in Sgcb-null atrium (At; G5, G2, and B5), ventricle (Ven; H4, B9, and B3), and aorta (Aor; A4, A9, and D10) clones. Protein ex-
tracts from C2C12 and embryo at 11 d postcoitum (dpc; E11) were used as positive controls. (B) Immunofluorescence analysis of three different Sgcb-null 
clones (G5 atrium, H4 ventricle, and A4 aorta) after 7 d of serum starvation. (C) Fusion index of Sgcb-null clones subjected to azacytidine (Aza) treatment JCB • VOLUME 193 • NUMBER 7 • 2011   1200
(black bars) and serum starvation (gray bars). (D) Western blot analysis for the expression of myogenin and cTnI (left) in the Sgcb-null atrium (G5) and 
ventricle (H4) clones. Extracts from C2C12 and cardiomyocytes (CM) were used as positive and negative controls. Scanner densitometry analysis on three 
independent experiments for myogenin and cTnI expression is shown on the right. (E) Proliferating (3 d) and differentiating (7 d) Sgcb-null ventricle clones 
were stained with MyoD (top) and myogenin (Myog; bottom). Muscle differentiation assay was performed in triplicates per each sample. (F) Field-stimulated 
twitches in wt cardiomyocytes, Sgcb-null ventricle clone (H4 Ven), and C2C12 cell line. Twitch acquisitions were represented as the arbitrary units (a.u.) 
during the perfusion of the control Tyrode solution, Ca
2+-free, and the return to the control conditions. Time courses of peak amplitudes in the condition of 
external 0 Ca
2+ are shown in the bottom graphs. The black bars represent time courses of peak amplitudes in condition of external 0 Ca
2+. The red lines 
represent the monoexponential fitting of time courses yielded time constant values (decay). (G) Cardiac sections from 9-mo-old Sgcb-null hearts (n = 4) 
were stained with anti-MyoD (top). Double staining of Sgcb-null cardiac sections with MyoD and cardiac MyHC (green) is shown at a lower magnification 
in the inset (top left). Double staining of Sgcb-null cardiac sections with MyoD and  sarcomeric actin (SA; bottom). Arrows indicate MyoD-positive nuclei 
in a 9-mo-old Sgcb-null heart. rel. expres., relative expression. Error bars show means ± SEM. Bars, 50 µm.
 
MyoD-positive cells were never detected in 2-d-old Sgcb-null 
hearts (Fig. S3 F), we strongly believe that cardiomyocytes of 
primary and secondary heart fields have additional molecular 
mechanisms to create a local microenvironment that suppress 
skeletal muscle differentiation of local cardiac progenitors in 
the early phase of the disease. Moreover, MyoD-positive nuclei 
were never revealed in normal hearts or in the hearts of mdx   
(X chromosome–linked muscular dystrophy) or -sarcoglycan–
null (Sgca-null) dystrophic mice (unpublished data) and, thus, 
are specifically related to the absence of the Sgcb gene.
miR669a overexpression rescues 
cardiac commitment in Sgcb-null cardiac 
progenitors both in vitro and in vivo
We then investigated the mechanism underlying skeletal myo-
genesis of Sgcb-null cardiac clones. Transduction of Sgcb-null 
cardiac progenitors with a lentiviral vector expressing Sgcb 
cDNA (KO + LVbSG) slightly inhibited MyoD expression in 
Sgcb-null cardiac clones (Fig. 2 A), although they maintained 
the ability to differentiate into skeletal muscle fibers (Fig. 2 B). 
This excluded a direct role of the SGCB protein in the regula-
tion of cardiac differentiation. However, typical alterations in 
Ca
2+ uptake measured in Sgcb-null clones were reverted in the 
presence of the SGCB protein because of restored membrane 
integrity (Fig. 2 C).
Because the Sgcb cDNA and protein were not able to res-
cue skeletal myogenesis, we evaluated alternative possibilities, 
such as differentially expressed miRNAs, which were analyzed 
by miRNA arrays as reported in Fig. S4 (A and B). Among the 
miRNAs  already  described  to  promote  skeletal  myogenesis, 
miR206 and miR133b were up-regulated in Sgcb-null cardiac 
clones in comparison with wt counterparts (Fig. S4 A). In addi-
tion, we evaluated the expression of muscle-related miRNAs in 
differentiating Sgcb-null cardiac progenitors (Fig. S5 G). miR1 
and miR133a involved in controlling differentiation and prolif-
eration of cardiac and skeletal muscle cells (Chen et al., 2005) 
were up-regulated and down-regulated, respectively. miR27b, a 
potent inhibitor of Pax3, was down-regulated to ensure rapid 
and  robust  entry  into  the  myogenic  differentiation  program 
(Crist et al., 2009). The expression of miR221 involved in dif-
ferentiation and maturation of skeletal muscle cells (Cardinali 
et al., 2009) didn’t change significantly, whereas miR208 ex-
pression (van Rooij et al., 2007) was not detected in prolifera-
tion or in differentiation conditions (unpublished data).
Interestingly, miR669a, which is highly expressed in wt 
cardiac progenitors, was almost absent in all Sgcb-null clones 
wt cells progressively up-regulated terminal cardiac differentia-
tion markers (Fig. S2 B; Galvez et al., 2008). Surprisingly, most 
of the Sgcb-null clones up-regulated MyoD and Myf5 skeletal 
muscle transcription factors but not late cardiac markers as 
shown by qPCR (Fig. S2 A), Western blot (Fig. 1 A and Fig. S2 B), 
and microarray analyses (deposited in GEO Datasets under ac-
cession no. GSE17774). Despite differences in marker expres-
sion, most of the Sgcb-null cardiac clones underwent robust 
skeletal myogenic differentiation after serum starvation as shown 
by immunofluorescence analysis (Fig. 1 B) and fusion index 
(Fig. 1 C and Video 1). Differentiation marker analysis indi-
cated that Sgcb-null clones expressed approximately half of the 
myogenin  level  detected  in  C2C12  myoblasts  but  did  not   
express cardiac troponin I (cTnI), normally present in mature car-
diomyocytes (Fig. 1 D). Immunofluorescence analysis confirmed 
MyoD and myogenin expression at early (3 d) and late (7 d) 
stages of differentiation (Fig. 1 E).
MyoD-negative ventricle clones (B3 and B9) rapidly up-
regulated MyoD, Myf5, and myogenin transcription factors dur-
ing differentiation (Fig. S2, C and D), and they efficiently fused 
into myotubes (Fig. S2 D). On the contrary, proliferating MyoD-
negative aorta clones (A4, A9, and D10) were positive for the 
expression of early endothelial genes (Fig. S2 E); in the condi-
tion of serum starvation, they did not undergo skeletal myogen-
esis, and upon TGF-1 treatment, they differentiated into smooth 
muscle cells (Fig. 1 B, right).
Furthermore, we analyzed the proliferation curves of 
Sgcb-null cardiac clones during 10 d of serum starvation. Cell 
mortality occurred after 8 d of differentiation because of the pau-
perization of medium nutrients (Fig. S2 F), when cells have   
totally fused into skeletal myotubes.
Dependency of contraction on extracellular Ca
2+ of differ-
entiated Sgcb-null cardiac progenitors (H4 Ven KO) was com-
pared with that of C2C12 and neonatal cardiomyocytes. Upon 
removal of Ca
2+, twitch amplitude gradually declined in H4 Ven 
KO by 50%, with a decay of 4.6 ± 0.8 s (n = 8). In C2C12, 
Ca
2+ decline was observed only in 3 of 10 cells, with a decay 
of 12.3 ± 5.1 s (n = 3). In contrast, Ca
2+ removal completely 
suppressed cell twitch in cardiomyocytes (decay = 0.8 ± 0.08 s; 
n = 7; Fig. 1 F). H4 Ven KO showed a contraction pattern com-
patible with skeletal-type excitation–contraction coupling.
This aberrant myogenic differentiation observed in vitro 
is recapitulated by the presence of MyoD-positive cells in de-
generative foci of 9-mo-old Sgcb-null hearts (Fig. 1 G and inset), 
where, however, terminal differentiation does not occur and 
multinucleated myofibers are not detected. Considering that 1201 Switch from cardiac to skeletal muscle lineages • Crippa et al.
Figure 2.  miR669a overexpression inhibits myogenic differentiation in Sgcb-null cardiac progenitors. (A) qPCR analysis for MyoD expression in wt trans-
duced Sgcb-null (KO + LVbSG) and Sgcb-null clones (KO; top). Western blot analysis for SGCB expression in differentiating wt, transduced Sgcb-null (KO + 
LVbSG), and Sgcb-null clones (KO; bottom). (B) Sgcb expression did not interfere with the ability of transduced Sgcb-null cardiac progenitors (+LVbSG) 
to form myotubes in serum starvation condition similar to not transduced cells (KO). (C) Time course of 
45Ca
2+ uptake into wt, transduced Sgcb-null (red 
line), and Sgcb-null cells (black line). (D) qPCR analysis for miR669a (top) and Sfmbt2 (bottom) expression in Sgcb-null (KO) and wt clones. Analysis was 
performed on three independent experiments. (E) miR669a expression in proliferating (prolif) and differentiating (white bars) wt and Sgcb-null (KO) cardiac 
clones.(F) Western blot analysis for YY1 expression in Sgcb-null (KO) and wt cardiac progenitors (top), in Sgcb-null progenitors treated with E64 for 48 
(KO+E64/48h) and 72 (KO+E64/72h) h, and in Sgcb-null progenitors transduced with LVbSG (bottom). (G) Relative (rel.) expression of miR669a (top) 
and Sfmbt2 (bottom) in Sgcb-null cardiac progenitors treated for 48 and 72 h with 100 µM E64 (white bars) and untreated (black bars). (H) miR669a 
(top) and Sfmbt2 (bottom) expression analysis in wt and in Sgcb-null cardiac progenitors transduced with LVbSG or LV-EGFP (KO). Ct, cycle threshold. 
(I) TaqMan assay analysis for miR669a and miR669q expression (top) and qPCR analysis for MyoD expression (bottom) in wt cardiac progenitors after 
transfection with scrambled (scr) miRNA and miR669a LNA knockdown (LNA). miR669a and miR669q silencing activated MyoD expression. (J) MyoD 
immunofluorescence analysis in the wt cardiac clone (J8 Ven WT) treated with scrambled miRNA (top) and with miR669a LNA (bottom). High magnification 
of MyoD-positive cells is shown in the insets. (K) miR669a (top) and MyoD (bottom) expression analysis in the Sgcb-null cardiac clone (KO) transfected with 
scrambled miRNA and miR669a. miR669a dramatically reduced MyoD expression in the miR669a-transfected Sgcb-null clone. (L) Immunofluorescence 
analysis for MyoD expression in the Sgcb-null cardiac clone transfected with scrambled miRNA (top) and miR669a (bottom). Three independent experi-
ments were performed in triplicates and statistically analyzed using Student’s t test; P < 0.05 in all panels. Error bars show means ± SEM. Bars, 50 µm.JCB • VOLUME 193 • NUMBER 7 • 2011   1202
Figure 3.  miR669q and miR669a prevent skeletal myogenesis in postnatal cardiac progenitors. (A) Schematic representation of miR669q within the Sgcb 
gene. Sequence homology between miR669a and miR669q encoded by the Sfmbt2 gene (intron 10) and by Sgcb (intron 1), respectively, is reported on 
the bottom. (B) miR669q expression in wt and Sgcb-null (KO) clones after 5 d of serum starvation (2% HS d5; left). Northern blot for miR669q expression 1203 Switch from cardiac to skeletal muscle lineages • Crippa et al.
transfected with pre-miR669a, MyoD expression was strongly 
down-regulated (Fig. 2 K, bottom) in miR669a-transfected cells 
(Fig. 2 K, top). MyoD-positive nuclei were no longer detected 
after  miR669a  transfection  in  Sgcb-null  cardiac  progenitors 
(Fig. 2 L). Similar results were obtained when Sgcb-null cardiac 
progenitors were transduced with a lentiviral vector carrying 
both EGFP and two copies of pre-miR669a (Fig. S3 A). Stable 
expression of miR669a (Fig. S3 B, left) in transduced Sgcb-null 
clones resulted in down-regulation of MyoD (Fig. S3B, right), 
miR206, and miR133b (not depicted) and up-regulation of cTnI 
(Fig. S3 B, right). When miR669a-transduced clones were induced 
to skeletal muscle differentiation, they failed to form myotubes 
(Fig. S3 C, left; and Video 2) and expressed cTnI (Fig. S3 C, 
right), indicating that the up-regulation of miR669a switches 
the differentiation program toward cardiac commitment.
Myogenic commitment was similarly inhibited in Sgcb-
null cardiac progenitors transfected with MyoD small hairpin 
RNA (shRNA; Fig. S3 D). Cardiac commitment was partially 
rescued by MyoD shRNA, although the number of cTnI-positive 
cells was extremely low (Fig. S3 D, bottom inset). The relation 
between deletion of the Sgcb gene and this miRNA appears to be 
indirect and hardly specific because most muscular dystrophies 
result in increased Ca
2+ entry and enhanced proteolysis. Thus, we 
examined in detail the structure of the Sgcb gene and identified   
a novel miRNA that we named miR669q, which is encoded in 
intron 1 of the Sgcb gene and homologous to miR669a (Fig. 3 A). 
miR669q showed a typical hairpin structure (Fig. S4 G) as pre-
dicted by mfold (Zuker and Jacobson, 1998).
For the generation of Sgcb-null mice, exons 3–6 were re-
placed by homologous recombination with the neomycin cas-
sette that makes the entire genetic locus unstable. Indeed, Sgcb 
transcripts were never detected in Sgcb-null cardiac and skeletal 
muscle, neither by Northern blotting nor RT-PCR, using a spe-
cific probe and primers for exon 2 (which is not deleted by the 
neomycin cassette; Durbeej et al., 2000).
miR669q was expressed in differentiated wt but not in dif-
ferentiated Sgcb-null cardiac progenitors (KO) as indicated by 
TaqMan assay (Fig. 3 B, left), Northern blot (Fig. 3 B, right), 
and in situ hybridization (Fig. 3 C) analyses. miR669q was ex-
pressed in the heart of wt and Sgca-null mice, a dystrophic ani-
mal model with a normal cardiac phenotype. On the contrary, 
miR669q was absent in Sgcb-null hearts, confirming that miR669q 
expression is abolished by a neomycin cassette inserted in the Sgcb 
gene. The absence of miR669q and miR669a down-regulation in 
derived from atria and ventricles (Fig. 2, D [top] and E; and 
Fig. S5 H). Slight differences in the miR669a expression profile   
are likely associated with different temporal stages toward mus-
cle differentiation of Sgcb-null clones.
We also observed that miR669a expression was also reduced 
in human cardiac progenitors isolated from patients affected by 
progressive cardiomyopathies (Fig. S5 I), whereas miR206 was 
up-regulated as shown in Fig. S5 J. Unfortunately, the miR669 
family is large and still poorly characterized in humans.
miR669a is encoded by the Sfmbt2 (Scm-like with four 
malignant brain tumor domains 2) gene, a member of polycomb 
group proteins involved in epigenetic silencing of skeletal muscle 
genes (Wu et al., 2007). Sfmtb2 showed the same expression 
profile of miR669a, suggesting that the miRNA and the host 
gene are cotranscribed (Fig. 2 D, bottom). It has been reported 
that the Sfmbt2 promoter is positively regulated by the tran-
scription factor Yy1 (Yinyang 1; Kuzmin et al., 2008). Consis-
tent with this finding, we observed that YY1 protein expression 
was strongly down-regulated in Sgcb-null (KO) compared with 
wt clones (Fig. 2 F, top). YY1 intracellular stability is proteolyt-
ically controlled by calpains, a group of nonlysosomal calcium-
dependent proteases (Galvagni et al., 1998; Walowitz et al., 
1998). The absence of the SGCB protein enhances intracellular 
calcium level and activates YY1 proteolytic degradation by cal-
pains. We indeed observed that YY1 transcription factor was 
up-regulated in Sgcb-null cardiac clones both when treated with 
the calpain inhibitor E64 (KO + E64) and after transduction 
with LVbSG as shown in Fig. 2 F (bottom).
Calpain inhibition (Fig. 2 G) and reduction of Ca
2+ uptake 
(Fig. 2 H) partially restored both miR669a and Sfmtb2 expres-
sion in treated Sgcb-null clones. Thus, gain- and loss-of-function 
experiments were performed to possibly correlate miR669a 
down-regulation in Sgcb-null clones with their myogenic com-
mitment. We abolished the expression of miR669a in wt cardiac 
progenitors (Fig. 2 I, top left) using the locked nucleic acid 
(LNA) knockdown system. Interestingly, miR669q expression 
(a so far uncharacterized member of the family; see following 
paragraph)  was  also  affected  by  miR669a  LNA  knockdown 
(Fig. 2 I, top right). The down-regulation of both miRNAs re-
sulted in the activation of skeletal myogenesis as demonstrated 
by robust activation of MyoD (Fig. 2 I, bottom) and confirmed 
by immunofluorescence analysis shown in Fig. 2 J, in which a 
higher magnification of MyoD-positive nuclei was reported in 
the inset. Conversely, when Sgcb-null cardiac progenitors were 
in differentiated wt and three differentiated Sgcb-null clones (H4, G5, and G2) confirmed the absence of miR669q in Sgcb-null cardiac progenitors (top 
right). miR669q signals were normalized for U2 snRNA hybridization. (C) miR669q in situ hybridization on serial sections from adult normal (wt heart) 
and dystrophic Sgcb-null and Sgca-null hearts. (D) Northern blot analysis confirmed the absence of miR669q and miR669a down-regulation in Sgcb-
null hearts. U2 snRNA hybridization was used for sample normalization. (E) MyoD expression analysis in the Sgcb-null cardiac clone transfected with 
scrambled miRNA, miR669a, and miR669q. Three independent experiments were performed in triplicates and statistically analyzed using Student’s t test.   
P < 0.05. (F) Western blot analysis for MyoD expression in Sgcb-null cardiac clone transfected with scrambled miRNA (H4 Ven KO) and miR669q.   
(G) Immunofluorescence analysis on Sgcb-null cardiac clone (H4 Ven KO) transfected with scrambled miRNA (left) and miR669q (right) 7 d after serum starvation 
(2% HS). (H) Luciferase (luc.) activity was measured in triplicates 24 and 48 h after COS-7 cell transfection with pre-miR669a/MyoD 3UTR (top left) and 
pre-miR669a/Pax3 3UTR (top right). Luciferase activity is indicated by black bars in scrambled transfected cells and by white bars in pre-miR669a/pre-
miR669q–transfected cells. Mutagenesis experiments were performed on MyoD 3UTR target sequence (MyoDm), and luciferase activity was measured in 
triplicates 24 h after transfection. Luciferase activity was relieved upon mutations of MyoD (gray bars) in both pre-miR669a (bottom left)– and pre-miR669q 
(bottom right)–transfected cells. Scrambled transfected cells were used as negative controls (ctrl). Error bars indicate standard deviation, and p-values are 
shown. (I) Schematic representation of the molecular mechanism responsible for the aberrant skeletal muscle differentiation in Sgcb-null cardiac progenitors. 
Active molecules are shown in green; no active molecules are shown in red. Error bars, except for H, show means ± SEM. Bars, 50 µm.
 JCB • VOLUME 193 • NUMBER 7 • 2011   1204
According to our findings, two molecular mechanisms are 
responsible for the aberrant skeletal muscle differentiation of 
Sgcb-null cardiac clones. The absence of miR669q, not expressed 
in Sgcb-null cardiac progenitors, and the down-regulation of 
miR669a, caused by the increased intracellular Ca
2+, deplete the 
cell of any negative regulators of MyoD expression (Fig. 3 I).
Next, we investigated the differentiation potential of Sgcb-
null cardiac progenitors in vivo (Table II). Hearts subjected to 
ischemic/reperfusion and cardiotoxin (ctx)-injured tibialis ante-
rior (TA) muscles were injected with 5 × 10
5 H4 KO/GFP and 
H4  KO/GFP/miR669  transduced  Sgcb-null  clones.  Hearts 
(Fig. 4, A and B) and TA muscles (Fig. 5, A and B) were col-
lected 7 d after injury to localize and evaluate the necrotic area 
and 5 wk later for immunofluorescence analysis. Transplanted 
hearts (Fig. 4 C) and TA muscles (Fig. 5 C) were macroscopi-
cally similar to sham-operated counterparts. Immunofluores-
cence analysis for Cx43/GFP on heart sections and laminin/GFP 
on  muscle  sections  clearly  showed  that  H4  KO/GFP  trans-
planted cells engrafted in both recipient cardiac (Fig. 4 E) and 
TA muscles (Fig. 5 E). The transplanted H4 KO/GFP/miR669 
cardiac clone integrated only in surviving cardiac tissue (Fig. 4 F) 
and was restricted into the interstitial compartment of injected 
TA muscles (Fig. 5 F). Quantification of donor cell engraftment 
is reported in Fig. 5 N. Interestingly, the Cx43 signal was uni-
formly distributed in sham-operated tissue (Fig. 4 D) together 
with GFP in H4 KO/GFP/miR669 transplanted hearts (Fig. 4 F, 
cellular resolution in the inset) but was detected only in GFP 
negative areas of H4 KO/GFP transplanted hearts (Fig. 4 E). 
Consistently, serial sections of H4 KO/GFP/miR669 transplanted 
cardiac tissue showed a large periinfarctual area positive for 
MyHC and Cx43 as highlighted in Fig. 4 I and with a higher 
magnification in Fig. 4 I. Conversely, H4 KO/GFP/miR669   
donor cells did not integrate with skeletal muscles fibers when 
transplanted in TA muscles. Double-positive MyHC/GFP mus-
cle fibers were not detected in H4 KO/GFP/miR669 transplanted 
mice (Fig. 5, I–I) similarly to the sham-operated mice (Fig. 5, 
G–G). On the other hand, H4 KO/GFP transplanted hearts 
showed several MyHC-positive multinucleated myofibers, which 
were characterized by the absence of Cx43 (Fig. 4, H [asterisks] 
Sgcb-null hearts (n = 3) was confirmed by Northern blot analy-
sis (Fig. 3 D).
miR669a and miR669q expression was further analyzed 
in developing embryos and in adult tissues. miR669q and 
miR669a were widely expressed in the embryonic heart at em-
bryonic day 13.5 (E13.5; Fig. S5, A and B); conversely, miR669q 
was not expressed in MyoD-positive somites at E11.5. MyoD 
and miR669q expression was mutually exclusive (Fig. S5 C,   
arrowheads). Low levels of miR669q expression colocalized with 
SMA-positive blood vessels in filter organs (Fig. S5, D–F).
miR669a/miR669q act as a coordinated and synergic 
system to prevent skeletal myogenesis in cardiac progenitors. 
Consistently, MyoD expression was strongly inhibited when 
Sgcb-null  clones  were  transfected  with  miR669a  or  with 
miR669q (Fig. 3, E and F). When miR669q-transfected Sgcb-
null progenitors were induced to differentiate by serum starva-
tion, they failed to fuse into myotubes, although some cells still 
expressed myosin heavy chain (MyHC), which does not dis-
criminate between cardiac and skeletal myogenesis (Fig. 3 G). 
Furthermore, MyoD expression was marginally up-regulated in 
wt cardiac progenitors transfected with antago miR669q, indi-
cating a redundant role of miR669a in MyoD inhibition (unpub-
lished data).
A direct interaction between miR669a and MyoD 3UTR 
was confirmed by reduced luciferase activity in COS-7 cells co-
transfected with pLuciferase-MyoD 3UTR, pre-miR669a, and 
pRL-cytomegalovirus (CMV) vector (used as a transfection   
efficiency control). No significant reduction of luciferase activ-
ity was observed when COS-7 cells were cotransfected with 
Pax3 3UTR (Fig. 3 H, top). Similar results were obtained with 
pre-miR669q–transfected cells (unpublished data).
Consistent with these observations, a target sequence for 
miR669a  and  miR669q  was  identified  within  the  3UTR  of 
MyoD (Fig. S4 E). Repression of luciferase activity was par-
tially relieved by mutations affecting MyoD 3UTR (Fig. S4 F) 
in pre-miR669a– and pre-miR669q–transfected cells (Fig. 3 H, 
bottom). The highly conserved central region of miR669a and 
miR669q mediates MyoD repression even in the absence of per-
fect seed pairing in both (Shin et al., 2010).
Table II.  Gene and cell therapy in in vivo experiments
Treated animals (strain) Sacrificed  
animals
Pretreatment Therapeutic  
approach
H4 KO cell  
manipulation
AAV2/9_Lacz virus
8 (Swiss nude) 8 CAL Sham  
8 (Swiss nude) 8 CAL Cell GFP 
9 (Swiss nude) 6 CAL Cell GFP/miR669 
10 (Swiss nude) 8 TA ctx Sham  
11 (Swiss nude) 8 TA ctx Cell GFP 
12 (Swiss nude) 6 TA ctx Cell GFP/miR669 
4 (Sgcb-null) 4  Gene  miR669
4 (Sgcb-null) 4  Gene  miRdsRed
12 (Swiss wt) 12 TA ctx Gene  miR669
12 (Swiss wt) 12 TA ctx Gene  miRdsRed
4 (Swiss wt) 3 TA ctx Oligo  miR669q
4 (Swiss wt) 3 TA ctx Oligo  SCR miRNAs
CAL, coronary artery ligation; Oligo, oligonucleotide miRNA precursor from Applied Biosystems; SCR, scramble. Minus signs indicate absence of that specific treatment.1205 Switch from cardiac to skeletal muscle lineages • Crippa et al.
cells was extremely reduced in H4 KO/GFP/miR669 (Fig. 5 M) 
and absent in sham transplanted muscle (Fig. 5 K).
To directly investigate the role of miR669a in muscle and 
cardiac regeneration, we injected AAV2/9-expressing miRdsRed 
(AAV2/9-nLacZ-miRdsRed2×)  as  a  control  or  pre-miR669a 
(AAV2/9-nLacZ-miR669a2×;  Fig.  6 A)  in  Sgcb-null  cardio-
myopathic hearts and in regenerating ctx-injured TA muscles. 
Sgcb-null hearts were analyzed 8 wk after virus injection. The 
reporter gene was widely expressed in all analyzed sections 
and H [arrows]), expression of skeletal MyHC (Fig. 4 H, higher 
resolution shown in the inset) and a large number of MyoD-
positive nuclei (Fig. 4 L). MyoD signal was rarely detected in 
H4 KO/GFP/miR669–treated hearts (Fig. 4 M) and not detected 
in sham-operated mice (Fig. 4 K). H4 KO/GFP cells participated 
in muscle regeneration as shown by the colocalization of GFP 
and MyHC signals (Fig. 5, H–H). MyoD-expressing fibers indi-
cated that regeneration was still ongoing in H4 KO/GFP trans-
planted TA (Fig. 5 L). The number of donor MyoD-positive 
Figure  4.  miR669a  overexpression  rescues 
cardiac commitment of Sgcb-null cardiac pro-
genitors  in  vivo.  (A)  Hematoxylin  and  eosin 
(H&E)  staining  of  heart  sections  after  isch-
emia/reperfusion.  (B)  Sirius  red  specifically 
stains scare tissue in infarcted hearts. (C) H&E-
stained  coronal  sections  of  infarcted  sham-
operated  hearts  (left)  and  infarcted  hearts 
transplanted with Sgcb-null cells (H4 KO/GFP; 
middle) or with Sgcb-null cells transduced with 
LVmiR669a  (H4  KO/GFP/miR669;  right).   
(D–M) Immunofluorescence analysis on infarcted 
hearts  of  sham-operated  mice  (D,  G,  G, 
and K), infarcted hearts after intraventricular 
transplantation of 5 × 10
5 H4 KO/GFP cells 
(E, H, H, and L); infarcted hearts after intra-
ventricle transplantation of 5 × 10
5 H4 KO/
GFP/miR669 (F, I, I, and M). Heart sections 
of untreated (D) and treated (E and F) mice 
were  stained  with  anti-Cx43  and  anti-GFP. 
H4 KO/GFP transplanted hearts (E) showed 
large GFP-positive and Cx43-negative cardiac 
areas.  On  the  contrary,  Cx43-positive  cells 
were  homogenously  distributed  in  the  sham-
operated  (D)  and  in  H4  KO/GFP/miR669 
transplanted hearts (F). In the inset (F), there 
is shown a higher magnification of GFP-positive 
cells  expressing  Cx43  that  are  integrated 
with the surviving cardiomyocytes. Heart sec-
tions of untreated (G) and treated (H and I) 
mice were stained with anti-MyHC and anti-
Cx43. High magnification of the highlighted 
areas in G, H, and I are reported in G, H, 
and I, respectively. H4 KO/GFP transplanted 
hearts showed the presence of polynucleated 
muscle fibers that did not express Cx43, as 
highlighted by the asterisk in H and arrows 
in H. In the inset (H), higher magnification is 
shown of skeletal MyHC-positive cells in a H4 
KO/GFP transplanted heart. On the contrary, 
sham-operated (G and G) and H4 KO/GFP/
miR669 transplanted hearts (I and I) showed 
Cx43 distributed all over the cardiac muscle. 
Heart sections from untreated (K) and treated   
(L and M) mice were analyzed for MyoD expres-
sion. MyoD-positive nuclei (arrows) are highly 
expressed in H4 KO/GFP transplanted heart 
sections (L), whereas they were completely ab-
sent in sham-operated heart sections (K) and 
extremely  reduced  in  H4  KO/GFP/miR669 
heart  sections  (M).  Bars:  (A,  B,  and  D–I)   
50 µm; (G–M) 100 µm.JCB • VOLUME 193 • NUMBER 7 • 2011   1206
Figure 5.  Myogenic potential of Sgcb-null cardiac 
progenitors  is  abolished  by  miR669a  overexpres-
sion in vivo. (A) H&E staining of ctx-injured TA mus-
cle sections. (B) Sirius red staining of fibrotic area   
in  muscle  sections  from  ctx-treated  TA  muscles.   
(C)  H&E-stained  coronal  sections  of  ctx-injured 
muscles sham-operated (left), transplanted with Sgcb-
null cells (H4 KO/GFP; middle), and with Sgcb-null 
cells  transduced  with  LV-CMV-EGFP-miR669a2× 
(H4  KO/GFP/miR669;  right).  (D–M)  Immuno-
fluorescence  analysis  on  the  ctx-treated  sham- 
operated  muscle  (D,  G–G,  and  K),  ctx-treated 
muscle after a single intramuscular injection of 5 × 
10
5 H4 KO/GFP cells (E, H–H, and L), and ctx-
treated muscle after a single intramuscular injection 
of 5 × 10
5 H4 KO/GFP/miR669 (F, I–I, and M). 
(D–F) TA muscles were analyzed for the expression 
of laminin and GFP. GFP-positive cells were specifi-
cally localized and integrated with muscle fibers in 
H4 KO/GFP–injected muscles (E). On the contrary, 
GFP-positive cells are restricted to interstitial compart-
ment  in  H4  KO/GFP/miR669-injected  muscles  (F).   
As expected, no GFP-positive cells were found in 
shame-operated  muscles  (D).  Sgcb-null  cardiac 
progenitors transplanted into ctx-damaged TA par-
ticipate in muscle regeneration. Higher magnifica-
tion GFP-positive fibers are reported in the inset.   
(G–I) Muscle sections from untreated (G) and treated   
(H and I) mice were stained with anti-MyHC and anti-
GFP. GFP-positive fibers were differently fused with 
skeletal muscle fibers in H4 KO/GFP transplanted 
muscles (H) and shown at a higher magnification in 
H and H. MyHC/GFP double-positive fibers were 
never detected in H4 KO/GFP/miR669 transplanted 
muscles, in which the only GFP-positive cells were   
localized in the interstitial and vessel compartment as 
shown in I–I. MyHC/GFP double-positive fibers or   
GFP-positive  cells  were  not  found  in  the  sham- 
operated muscles (G–G). (K–M) MyoD expression 
was analyzed in untreated (K) and treated (L and M) 
TA muscles. MyoD was strongly expressed in H4 KO/
GFP transplanted muscle fibers (L) and extremely re-
duced in untreated (K) and in H4 KO/GFP/miR669 
(M)  transplanted  muscle  fibers.  Arrows  indicate 
MyoD-positive nuclei. (N) Cell counts of GFP/MyHC 
double-positive cells were performed on muscle and 
cardiac sections from transplanted mice. Six mice 
per  each  group  of  treatment  were  independently 
and  statistically  analyzed  using  Student’s  t  test   
(P < 0.05). Sk.Mu, skeletal muscle; Ven, ventricle. 
Error bars show means ± SEM. Bars: (A, B, and D–I) 
50 µm; (G–M) 100 µm.1207 Switch from cardiac to skeletal muscle lineages • Crippa et al.
Figure 6.  Overexpression of miR669a ameliorates the dystrophic cardiac phenotype in Sgcb-null hearts. (A) Schematic representation of AAV2/9-TF-
CBA-nLacZ-mi669a2×/miRdsRed2×. 2-d-old Sgcb-null mice were injected intraventricularly and analyzed 8 wk later (B–L). X-gal reaction, miR669a in 
situ hybridization, and H&E and Azan-Mallory (AM) staining on heart sections from miRdsRed (B–E)- and miR669a (F–I)-injected animals. miR669a was JCB • VOLUME 193 • NUMBER 7 • 2011   1208
Cardiac progenitors from Sgcb-null hearts undergo this 
aberrant differentiation because they lack two key regulatory 
microRNAs, miR669a and miR669q, which are capable of sup-
pressing skeletal myogenesis (Fig. 3, Fig. 4, and Fig. 5). miR669a 
is encoded and cotranscribed with the host gene Sfmbt2, which 
we found down-regulated in Sgcb-null cardiac progenitors because 
of a signal cascade involving intracellular calcium, calpain prote-
ases, and degradation of YY1, a positive regulator for Sfmbt2.
The high level of intracellular Ca
2+ activates calpain pro-
teases responsible for YY1 proteolytic degradation (Galvagni   
et al., 1998; Walowitz et al., 1998) in most dystrophic muscle cells 
(Sampaolesi et al., 2001). On the contrary, miR669q expression 
is abolished exclusively in Sgcb-null cardiac progenitors, de-
pleting the cell of any negative regulator of MyoD expression.
Dysregulation of both miRNAs is necessary to activate 
skeletal myogenesis in Sgcb-null cardiac progenitors. Of notice, 
miR669a and miR669q are the first identified miRNAs that act 
upstream of MyoD, thus indirectly regulating all MyoD targets.
When  cardiac  progenitors  from  dystrophic  mice  were 
transplanted into female nude mice after focal damage caused 
by ctx treatment in skeletal muscle and coronary ligation in the 
heart, they readily engrafted into cardiac and skeletal muscles. 
Donor-derived Sgcb-null cells were unable to restore cardiac 
tissue and persistently differentiated in skeletal muscle that al-
tered the regular heart beating (Video 3). Skeletal myoblasts 
have been shown to do so in an infarcted human heart even 
though they elicit a functional benefit (Menasché et al., 2008). 
The inability of Sgcb-null cardiac progenitors to differentiate 
into cardiomyocytes after transplantation into an injured heart 
demonstrates that their normal differentiation potential has been 
subverted and a regenerating cardiac environment is not suffi-
cient to rescue it. It thus becomes important to ask why skeletal 
muscle does not form aberrantly in the heart of Sgcb-null mice. 
Probably, cardiomyocytes of primary and secondary heart fields 
have additional molecular mechanisms to suppress skeletal myo-
genesis and, thus, create a local microenvironment that suppresses 
the skeletal muscle differentiation of local cardiac progenitors. 
This theory is consistent with a large number of apoptotic cells 
in regeneration/degeneration foci of the dystrophic heart, in which 
MyoD-expressing cells are detected during the progression of 
the disease. This may explain, at least in part, the failure of car-
diac progenitors to efficiently counteract cardiac degeneration 
in Sgcb-null mice and may relate to aberrant MyoD expression 
in oncocytic (Hotárková et al., 2004) and Myf5-induced cardio-
myopathy (Santerre et al., 1993).
So far, no function was associated with the miR669 fam-
ily. Here, we show that both miR669a and the novel miR669q 
are critical to prevent skeletal muscle differentiation in cardiac 
tissue. This would suggest that skeletal myogenesis is dominant 
(Fig. 6, B and F), whereas miR669a was specifically expressed 
in miR669a-injected hearts (Fig. 6, C and G). We observed 
amelioration in tissue histology and a delay in the onset of car-
diac degeneration (Fig. 6, compare D and E with H and I).   
Necrotic  foci  normalized  for  section  area  were  quantified 
and reported in Fig. 6 O, showing a reduction of necrosis in 
miR669a-overexpressing Sgcb-null hearts. Immunofluores-
cence analysis for Cx43 and MyHC also confirmed improved 
sarcomeric organization (Fig. 6, compare J with L). Further-
more, the number of apoptotic nuclei was dramatically reduced 
as shown by TUNEL assay (Fig. 6, compare K and K with   
M and M) and quantified as the percentage of total nuclei per 
section (Fig. 6 N).
Conversely, in skeletal muscle regeneration, we observed 
a negative effect of miR669a overexpression that resulted in 
less efficient muscle regeneration (Fig. 7, A–I). 21 d after viral 
injection, treated muscles showed a wide expression of the re-
porter gene (Fig. 7, A and D). Smaller (Fig. 7, compare B and E) 
and  central  nucleated  fibers  positive  for  -galactosidase   
(Fig. 7, compare C and C with F and F) were observed in 
miR669a-injected muscles, revealing a delay of muscle regen-
eration specifically induced by miR669a and quantified by 
morphometric analysis in Fig. 7 I. miR669a-mediated down-
regulation of MyoD results in MyHC reduction (Fig. 7 G) as 
quantified by scanner densitometry in Fig. 7 H. Similar results 
were obtained for ctx-injured TA after miR669q injection (n = 3). 
Analyzed muscle sections showed higher numbers of centro-
nucleated fibers (Fig. S3 E, arrows), which were smaller in 
diameter and positive for embryonic MyHC (Fig. S3 E, arrow-
heads) compared with scramble-treated muscles. Collectively, 
these results show that overexpression of miR669a is able   
to rescue, at least partially, cardiac degeneration in Sgcb-null 
mice by inhibiting MyoD expression that otherwise impairs   
cardiac progenitors. A delay of skeletal muscle regeneration 
confirms the important role of those specific miRNAs in myo-
genesis regulation.
Discussion
Together, our data unequivocally show that cardiac progenitors 
isolated from a mouse model of muscular dystrophy with car-
diac involvement (LGMD2E) undergo aberrant differentiation 
toward skeletal muscle both in vitro and in vivo, independent of 
the site of transplantation (i.e., cardiac or skeletal muscle).   
Lineage promiscuity between skeletal and cardiac myogenic pro-
genitors is extremely rare and has been reported only in a single 
study in which progenitor cells from adult murine skeletal muscle 
could be induced to differentiate into beating cardiomyocytes 
(Winitsky et al., 2005).
specifically expressed in miR669a-injected Sgcb-null hearts (C and G). Necrotic foci and fibrotic area extension were reduced in miR669a (H and I) 
compared with miRdsRed (D and E)-treated Sgcb-null hearts, assuming a benefic role of miR669a overexpression in cardiac pathology progression. Immuno-
fluorescence analysis for MyHC and Cx43 expression in miRdsRed (J)- and miR669a (L)-injected Sgcb-null hearts. TUNEL assay analysis on miRdsRed   
(K and K)- and miR669a (M and M)-injected Sgcb-null hearts. Apoptotic nuclei are shown in green and highlighted by arrows in K and K. (N) Percentage 
of apoptotic nuclei on cardiac sections from miRdsRed- and miR669a-injected Sgcb-null hearts. Three mice per each group of treatment were independently 
and statistically analyzed using Student’s t test (P < 0.01). (O) Percentage of necrotic foci on total cardiac section of miRdsRed- and miR669a-injected 
Sgcb-null hearts. Four mice per each group of treatment were independently and statistically analyzed. Bars, 50 µm.
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Figure 7.  Overexpression of miR669a delays skeletal muscle regeneration in ctx-injured TA muscles. TA muscles of 7-d-old Swiss mice were ctx injured, 
injected intramuscularly with AAV2/9-nLacZ-miR669a2× (miR669a), and analyzed 7, 14, and 21 d after injury. AAV2/9-nLacZ-miRdsRed2× (miRdsRED) 
was used as a negative control. (A, B, D, and E) X-gal reaction on miRdsRed (A) and miR669a (D) treated muscle sections. Laminin expression in miRdsRed 
(B)- and miR669a (E)-treated muscle sections. miR669a-treated muscles showed smaller fibers compared with control muscles. (C, C, F, and F) Laminin JCB • VOLUME 193 • NUMBER 7 • 2011   1210
Inhibition and activation of myogenic differentiation
Skeletal muscle differentiation was inhibited in Sgcb-null and activated in wt 
cardiac  progenitors  by  transfection  with  pre-miR669a  (Invitrogen)  and 
miR669a LNA knockdown transfection (Exigon), respectively, according to 
the Lipofectamine 2000 manufacturer’s instructions (Invitrogen).
Lentiviral vector production and Sgcb-null cardiac progenitor transduction
Lentiviral vector encoding Sgcb (LV-CHMWS-Sgcb-IRES-GFP) was generated 
by PCR amplification of differentiated C2C12 cDNA using the following 
primers: Sgcb forward, 5-AAAAAAAGATCTATGGCGGCAGCGGCGGC-
GGGCG-3,  and  reverse,  5-AAAAAATCTAGACTAATGAGTGTTCCCA-
CAAGGGTTGTC-3. The unique restriction sites XbaI and BglII were added 
to the 5 and 3 ends of Sgcb forward and Sgcb reverse primers, respec-
tively. After amplification, the Sgcb PCR product was digested with XbaI 
and BglII and cloned into the pCHMWS-IRES-GFP digested with BamHI and 
NheI, which generate compatible ends for XbaI and BglII, respectively.
Lentiviral  vector  encoding  two  copies  of  pre-miRNA669a  was 
generated by PCR amplification of the pre-miRNA669a template using   
the following primers: miR669a forward, 5-AAAAAAGATCTCGAGATT-
CCTCCATGTATGTGCATGTGTGTATAGTTGTG-3, and reverse, 5-AAAA-
AAGGATCCAAGTCGACTGTGTCTGTGTATGTGTGCTTGCGTTTATACGT-
GTG-3. The unique restriction sites BglII–XhoI and BamHI–SalI were added 
to the 5 and 3 ends of miR669a forward and miR669a reverse primers, 
respectively. After amplification, the pre-miR669a PCR product was di-
gested with XhoI and BamHI and inserted two times into the transfer 
plasmid pN3-MCS-WPRE-EGFP C12. The 2× pre-miR669a fragment was 
excised using XhoI and KpnI and cloned into pCHMWS-EGFP digested 
with the same restriction enzymes, resulting in LV-CHMWS-EGFP–pre-
miRNA669a2×. Third generation lentiviral particles were generated by 
transient transfection in 293T cells and were used to infect Sgcb-null 
clones at MOI 50. GFP was used as a standard gene expression tracer for 
in vivo experiments.
Adeno-associated vector production and injection into injured muscles 
and cardiomyopathic hearts
An adaptor containing ApaI and AsuII restriction sites was generated by 
the annealing of the following primers: adaptor adeno-associated viral 
vector  forward,  5-TCGAAGCTTACCGGTACTAGTGGGCCCAATTGTTC-
GAAGC-3, and reverse, 5-GGCCGCTTCGAACAATTGGGCCCACTAG-
TACCGGTAAGCT-3,  and  ligated  into  SalI–NotI-digested  pN3-WPRE- 
EGFP-miR669a2× C12 transfer plasmid. The miR669a2× cassette was 
excised using NheI and ApaI and cloned into pAAV-EnhCB-LacZnls di-
gested  with  the  same  restriction  enzymes.  AAV2/9-lacZnls-miR669a2×   
viral particles were used to inject TA muscle 5 d after ctx injury (10
9 trans-
duction units) and to inject intraventricular Sgcb-null hearts affected by car-
diomyopathy (10
9 transduction units). AAV2/9-lacZnls-miRdsRed2× was 
produced with the same protocol and used as a negative control.
Northern blot analysis
The miRNA population was isolated from proliferating and differentiated 
wt and Sgcb-null cardiac clones and hearts according to an miRNA isola-
tion kit (PureLink; Invitrogen). 1 µg miRNA sample was heated at 95°C for 
5 min and run on denaturating acrylamide gel (15 ml of gel; 1.5 ml of 10× 
TBE  (Tris/borate/EDTA)/8  M  urea,  5.6  ml  acrylamide/bisacrylamide 
[19:1], 75 µl ammonium persolphate, 15 µl tetramethylethylenediamine, 
and H2O to final volume) at 100 V until bromophenol blue reached the 
bottom of the gel (90 min). After ethidium bromide staining of polyacryl-
amide gels, the tRNA and 5 and 5.8 S RNA bands were visualized under 
a UV transilluminator and served as loading controls. Then miRNAs were 
transferred to a nylon membrane (Hybond-N+; GE Healthcare) by electro-
blotting for 2 h at 200 mM. RNA was then UV cross-linked to the nylon 
membrane (120-mJ burst for 1 min.). miR669a and miR669q were de-
tected on a Northern blot using specific [P
32]ATP-labeled probes. After 2 h 
at 37°C in prehybridization solution (6× SSC, 10× Denhardt’s solution, 
and 0.2% SDS), the membrane was incubated for 24 h in the hybridization 
(possibly because of the dominant nature of MyoD) and re-
quires active suppression in closely related mesoderm lineages 
that express many common regulatory factors. These experi-
ments lead to the conclusion that miR669a and miR669q regu-
late the cell fate of cardiac progenitors by directly targeting 
MyoD expression through their central region.
Redundancy of the miR669a/miR669q system and two 
different regulation mechanisms guarantee a tight inhibition of 
the skeletal myogenic program in cardiac progenitors, in which 
it is not required. Calpain activation in Sgcb-null cardiac pro-
genitors reduced the expression of miR669a and all the mem-
bers of the 669 cluster that are encoded in the Sfmbt2 gene and 
share homology with miR669a in the central region. Conversely, 
miR669q is cotranscribed with the Sgcb gene in muscle cells 
and not regulated by calpains. However, the role of miR669a 
and miR669q in skeletal muscle homeostasis and physiological 
relevance is currently under investigation.
In conclusion, at least two members of miR669 family, 
miR669a and miR669q, are capable of repressing skeletal myo-
genesis in wt cardiac progenitors by directly inhibiting MyoD 
expression, revealing a mechanism that had not been described 
or predicted until now. Although these data indicate that the 
simple scheme isolation–genetic correction–autologous trans-
plantation may not work in all cases, it also raises intriguing 
questions about human LGMD2E that remain to be addressed 
but depend upon the extremely problematic availability of car-
diac biopsies from these patients and the fact that the miR669 
family has not yet been characterized in human hearts.
Materials and methods
Isolation and skeletal muscle differentiation of Sgcb-null  
cardiac progenitors
Sgcb-null mice were generated by the group of K.P. Campbell (University 
of Iowa, Iowa City, IA). Hearts isolated from 2-wk Sgcb-null mice were 
kept in DME without FCS with antibiotics and divided in three different 
pieces: aorta, ventricle, and atrium. Each piece was rinsed in PBS with 
Ca
+/Mg
+ and sharply dissected into 1–2-mm-diameter pieces with a scal-
pel. Fragments containing small vessels were transferred to a Petri dish 
coated with 1% gelatin in the presence of 20% FBS-DME plus 5 mM glu-
tamine and antibiotics. These heart fragments were cultured for 8–15 d 
depending on the region, and after the initial outgrowth of fibroblast-like 
cells, small round and refractile cells appeared. This cell population was 
easily collected by gently pipetting of the original culture, counted, and 
cloned by limited dilution on 1% gelatin-coated p96 well dishes. Different 
valid clones were selected by phase-contrast morphology. In some experi-
ments, cells were prospectively isolated from collagenase-digested neo-
natal hearts by the expression of c-Kit following a previously published 
protocol (Beltrami et al., 2001). The cells obtained showed a similar pheno-
type to those isolated by the explant methods.
Skeletal  muscle  differentiation  was  induced  by  5azacitydine 
and, spontaneously, in differentiation medium (DME 2% horse serum 
[HS]). After 7 d, cultures were fixed and stained with antibodies against 
MyHC  and  MyoD.  Western  blot  analysis  was  performed  using  the 
same antibodies.
and -galactosidase expression on miRdsRed (C and C)- and miR669a (F and F)-injected muscle sections. Muscle fibers with central position of -galactosidase– 
positive nuclei were predominantly found in miR669a-treated muscles (F). (G) MyHC, MyoD, and Pax7 expression analysis on protein extracts from 
miRdsRed- and miR669a-injected muscle. (H) Relative quantification for MyHC, MyoD, and Pax7 expression in miRdsRed- and miR669a-treated muscles. 
P-values are shown (*, P < 0.01; **, P < 0.05). (I) Morphometric analysis of muscle fibers areas at 7, 14, and 21 d after injury in miRdsRed- and miR669a-
injected muscles. It is remarkable that the averaged area of miR669a-treated muscle fibers is extremely reduced (300–500 µm
2) compared with the control 
muscle fibers (1,000–1,500 µm
2). Four mice per each group of treatment were independently and statistically analyzed using Wilcoxon-Matt-Whitney test 
(P < 0.001). Error bars show means ± SEM. Bars: (A, B, D, and E) 50 µm; (C, C, F, and F) 100 µm.
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myotubes. Video 2 shows that miR669a overexpression inhibits skeletal 
differentiation in Sgcb-null cardiac progenitors. Video 3 shows echocar-
diogram analysis on nude mice transplanted with Sgcb-null cardiac pro-
genitors.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.201011099/DC1.
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solution containing >4 × 10
5 cpm labeled antisense probe (6× SSC, 5× 
Denhardt’s solution, 1–5 × 10
6 cpm, and 0.2% SDS). After hybridization, 
the blot was washed in 6× SSC and 0.2% SDS washing solution three 
times at 50°C. After the final wash, the blot was exposed to x-ray film. 
miR669q signals were normalized for U2 small nuclear RNA (snRNA;   
5-TTAGCCAAAAGGCCGAGAAGC-3) hybridization.
miRNAs in situ hybridization
Serial frozen sections from embryos and adult tissues were hybridized 
overnight at 59°C with biotinylated miR669a/miR669a-like probes previ-
ously denatured for 10 min at 70°C in hybridization buffer (200 mM NaCl, 
50% formamide, 10% dextran sulfate, 1 mg/ml yeast tRNA, and Denhardt’s 
solution). After 3× 30-min washes in SSC, 50% formamide, and 0.1% 
Tween, miRNA expression signals were detected using 488 fluorochrome-
conjugated streptavidin. Nuclei were stained in blue with DAPI.
Luciferase activity detection
The 3UTR of MyoD1 and Pax3 mRNA were cloned into the pMIR-REPORT 
vector  (Invitrogen).  COS-7  cells  were  cotransfected  with  pMIR-REPORT-
MyoD1-3UTR/pMIR-REPORT-Pax3-3UTR and pre-miR669a (Invitrogen) ac-
cording to the Lipofectamine 2000 manufacturer’s protocol. miRNA scramble 
precursor was used as a negative control, whereas the pRL-CMV vector was 
used as an internal control for transfection efficiency. Luciferase activity was 
detected according to the Dual-Luciferase Reporter Assay System (Promega).
Mutagenesis on MyoD 3UTR
Mutagenesis experiments were performed according to a site-directed muta-
genesis kit (QuickChange II XL; Agilent Technologies). Primers were designed 
as follows: forward (351CAC353-351TTT353), 5-GCACAGGGGTGA-
GCCTTGTTTACCTAAGCCCTGCCCTC-3,  and  reverse  (351CAC353-
351TTT353),  5-GAGGGCAGGGCTTAGGTAAACAAGGCTCACCCCT-
GTGC-3. These primers inserted specific mutations in the 3UTR of MyoD 
(mMyoD). The pMIR-REPORT-mMyoD 3UTR was further amplified by bacterial 
transformation and selected according to the manufacturer’s protocol.
miR669q muscle injections
Adult 4-wk-old male Swiss mice were anesthetized by i.p. injection of a 
mixture of 5 mg/ml ketamine and 1 mg/ml xylazine. TA muscles were in-
jected with a 100-µl solution containing 10 µM ctx and 10 µg of either 
miR669q and scramble miRNAs (Invitrogen). 21 d after injection, TA mus-
cles were dissected and immediately frozen in isopentane cooled in liquid 
nitrogen and stored at 80°C for further analysis.
Microscope image acquisition
Image acquisition was performed with a fluorescent inverted microscope 
(Eclipse Ti-U; Nikon) equipped with a camera (QICAM Fast 1354; QImag-
ing) using Image-Pro Plus software (Media Cybernetics) and CFI Achromat 
Series objective lenses (Nikon) detailed as follows: CFI Achromat 10×,   
NA 0.25; CFI Achromat LWD 20×, NA 0.40; and CFI Achromat 60×,   
NA 0.80. Transmitted light microscopy images were collected using phase-
contrast objectives and rings. When direct comparisons of fluorescence 
signal levels were needed, wt and knockout treated and untreated cells 
were processed side by side, and images were collected the same day 
using constant exposure times. Images were imported in Photoshop (Adobe), 
assembled in montages, and enhanced for levels, brightness, and contrast 
simultaneously to preserve the differences in the signal observed in the 
original data.
Images of differentiating cells were analyzed by time-lapse confocal 
microscopy using a confocal microscope (BioStation IM-Q; Nikon). Cells 
were maintained in differentiation condition (DME 2% HS), 5% CO2, and 
95% humidity for 3 d. Frames were taken every 30 min and analyzed ac-
cording to the NIS-Elements Advanced Research software (Nikon).
Statistical analysis
Results are given as means ± SEM. Statistical significance was tested using 
one-way analysis of variance and Student’s t test, moderate t statistic, and 
limma statistic.
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Fig. S1 shows isolation and characterization of Sgcb-null cardiac progeni-
tors. Fig. S2 shows characterization of Sgcb-null aorta and ventricle clones. 
Fig. S3 shows inhibition of myogenic differentiation in Sgcb-null cardiac 
progenitors. Fig. S4 shows miRNA expression profiling in wt and Sgcb-
null cardiac progenitors. Fig. S5 shows the miRNA expression profile in   
embryonic/adult tissues and in mouse/human cardiac progenitors. Video 1 
shows that Sgcb-null cardiac clones aberrantly differentiate into skeletal JCB • VOLUME 193 • NUMBER 7 • 2011   1212
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